Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth L Bond

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survivalLukasz F Grochola, Alexei Vazquez, Elisabeth E Bond, et al.
Cancer Research|March 6, 2012
A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcomaKaren S Yee, Lukasz Grochola, Garth Hamilton, et al.
Cancer Research|December 10, 2009
Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survivalAlexei Vazquez, Lukasz F Grochola, Elisabeth E Bond, et al.
The Journal of Biological Chemistry|May 24, 2005
A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cellsNicoleta C Arva, Tamara R Gopen, Kathryn E Talbott, et al.
Cancer Cell|September 14, 2010
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor developmentSean M Post, Alfonso Quintás-Cardama, Vinod Pant, et al.
Cancer Research|May 19, 2006
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent mannerGareth L Bond, Kim M Hirshfield, Tomas Kirchhoff, et al.
Cell Reports|May 7, 2016
A Polymorphic Antioxidant Response Element Links NRF2/sMAF Binding to Enhanced MAPT Expression and Reduced Risk of Parkinsonian DisordersXuting Wang, Michelle R Campbell, Sarah E Lacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2016
CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal AdenocarcinomaGiovanni Stracquadanio, Bart Vrugt, Renata Flury, et al.
Genome Biology|May 24, 2023
Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancerAnna J Wiecek, Stephen J Cutty, Daniel Kornai, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Haplotype structure and selection of the MDM2 oncogene in humansGurinder Singh Atwal, Gareth L Bond, Sally Metsuyanim, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survivalLukasz F Grochola, Alexei Vazquez, Elisabeth E Bond, et al.
Cancer Research|March 6, 2012
A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcomaKaren S Yee, Lukasz Grochola, Garth Hamilton, et al.
Cancer Research|December 10, 2009
Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survivalAlexei Vazquez, Lukasz F Grochola, Elisabeth E Bond, et al.
The Journal of Biological Chemistry|May 24, 2005
A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cellsNicoleta C Arva, Tamara R Gopen, Kathryn E Talbott, et al.
Cancer Cell|September 14, 2010
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor developmentSean M Post, Alfonso Quintás-Cardama, Vinod Pant, et al.
Cancer Research|May 19, 2006
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent mannerGareth L Bond, Kim M Hirshfield, Tomas Kirchhoff, et al.
Cell Reports|May 7, 2016
A Polymorphic Antioxidant Response Element Links NRF2/sMAF Binding to Enhanced MAPT Expression and Reduced Risk of Parkinsonian DisordersXuting Wang, Michelle R Campbell, Sarah E Lacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2016
CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal AdenocarcinomaGiovanni Stracquadanio, Bart Vrugt, Renata Flury, et al.
Genome Biology|May 24, 2023
Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancerAnna J Wiecek, Stephen J Cutty, Daniel Kornai, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Haplotype structure and selection of the MDM2 oncogene in humansGurinder Singh Atwal, Gareth L Bond, Sally Metsuyanim, et al.
Pageof 4